Alimera Sciences, Inc. (ALIM)
USD 5.54
(-0.18%)
USD 5.54
(-0.18%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -20.13 Million USD | -11.18% |
| 2022 | -18.1 Million USD | -314.16% |
| 2021 | -4.37 Million USD | 18.11% |
| 2020 | -5.33 Million USD | 48.87% |
| 2019 | -10.44 Million USD | 36.26% |
| 2018 | -16.38 Million USD | 25.54% |
| 2017 | -22 Million USD | 33.68% |
| 2016 | -33.17 Million USD | -8.25% |
| 2015 | -30.64 Million USD | 14.66% |
| 2014 | -35.91 Million USD | 22.32% |
| 2013 | -46.22 Million USD | -134.12% |
| 2012 | -19.74 Million USD | 12.3% |
| 2011 | -22.51 Million USD | -62.46% |
| 2010 | -13.85 Million USD | 68.66% |
| 2009 | -44.21 Million USD | 28.06% |
| 2008 | -61.46 Million USD | -977.37% |
| 2007 | -5.7 Million USD | 56.02% |
| 2006 | -12.97 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -6.25 Million USD | -65.33% |
| 2024 Q2 | -3.31 Million USD | 47.03% |
| 2023 Q4 | -3.78 Million USD | -179.25% |
| 2023 Q3 | -1.35 Million USD | 86.5% |
| 2023 FY | -20.13 Million USD | -11.18% |
| 2023 Q1 | -8.3 Million USD | -119.6% |
| 2023 Q2 | -10.02 Million USD | -20.82% |
| 2022 Q2 | -3.11 Million USD | 59.87% |
| 2022 Q4 | -3.78 Million USD | 28.1% |
| 2022 Q1 | -7.76 Million USD | -89.06% |
| 2022 Q3 | -5.25 Million USD | -68.76% |
| 2022 FY | -18.1 Million USD | -314.16% |
| 2021 Q4 | -4.1 Million USD | 1.84% |
| 2021 Q2 | 6.98 Million USD | 291.58% |
| 2021 Q1 | -3.64 Million USD | -273.39% |
| 2021 FY | -4.37 Million USD | 18.11% |
| 2021 Q3 | -4.18 Million USD | -159.85% |
| 2020 Q1 | -1.19 Million USD | -340.56% |
| 2020 Q2 | -2.54 Million USD | -112.52% |
| 2020 Q3 | -618 Thousand USD | 75.73% |
| 2020 Q4 | -977 Thousand USD | -58.09% |
| 2020 FY | -5.33 Million USD | 48.87% |
| 2019 Q2 | -5.03 Million USD | -82.34% |
| 2019 Q1 | -2.76 Million USD | -121.22% |
| 2019 Q4 | 498 Thousand USD | 115.86% |
| 2019 FY | -10.44 Million USD | 36.26% |
| 2019 Q3 | -3.14 Million USD | 37.67% |
| 2018 Q3 | -3.45 Million USD | 13.75% |
| 2018 FY | -16.38 Million USD | 25.54% |
| 2018 Q1 | -7.68 Million USD | -6.37% |
| 2018 Q2 | -4 Million USD | 47.94% |
| 2018 Q4 | -1.24 Million USD | 63.8% |
| 2017 FY | -22 Million USD | 33.68% |
| 2017 Q4 | -7.22 Million USD | -36.69% |
| 2017 Q3 | -5.28 Million USD | -91.69% |
| 2017 Q2 | -2.75 Million USD | 59.06% |
| 2017 Q1 | -6.73 Million USD | -13.65% |
| 2016 Q4 | -5.92 Million USD | 35.9% |
| 2016 FY | -33.17 Million USD | -8.25% |
| 2016 Q1 | -11.14 Million USD | -4.03% |
| 2016 Q3 | -9.24 Million USD | -34.81% |
| 2016 Q2 | -6.85 Million USD | 38.47% |
| 2015 Q4 | -10.71 Million USD | -594.3% |
| 2015 FY | -30.64 Million USD | 14.66% |
| 2015 Q1 | -9.79 Million USD | -5.78% |
| 2015 Q2 | -8.59 Million USD | 12.22% |
| 2015 Q3 | -1.54 Million USD | 82.05% |
| 2014 Q2 | 1.11 Million USD | 105.38% |
| 2014 Q4 | -9.25 Million USD | -32.09% |
| 2014 Q3 | -7 Million USD | -728.05% |
| 2014 Q1 | -20.75 Million USD | -40.51% |
| 2014 FY | -35.91 Million USD | 22.32% |
| 2013 FY | -46.22 Million USD | -134.12% |
| 2013 Q2 | -16.36 Million USD | -17.01% |
| 2013 Q3 | -1.11 Million USD | 93.2% |
| 2013 Q4 | -14.77 Million USD | -1227.4% |
| 2013 Q1 | -13.98 Million USD | -164.4% |
| 2012 Q2 | -4.7 Million USD | -7.82% |
| 2012 Q1 | -4.36 Million USD | 28.17% |
| 2012 Q4 | -5.28 Million USD | 1.95% |
| 2012 FY | -19.74 Million USD | 12.3% |
| 2012 Q3 | -5.39 Million USD | -14.72% |
| 2011 FY | -22.51 Million USD | -62.46% |
| 2011 Q3 | -6.54 Million USD | -25.58% |
| 2011 Q2 | -5.2 Million USD | -10.88% |
| 2011 Q1 | -4.69 Million USD | 24.88% |
| 2011 Q4 | -6.07 Million USD | 7.17% |
| 2010 Q2 | -4.1 Million USD | -259.14% |
| 2010 Q1 | 2.57 Million USD | 111.37% |
| 2010 Q4 | -6.25 Million USD | -2.81% |
| 2010 FY | -13.85 Million USD | 68.66% |
| 2010 Q3 | -6.08 Million USD | -48.31% |
| 2009 Q3 | -5.11 Million USD | 18.45% |
| 2009 Q4 | -22.66 Million USD | -343.52% |
| 2009 FY | -44.21 Million USD | 28.06% |
| 2009 Q1 | -10.17 Million USD | 24.77% |
| 2009 Q2 | -6.26 Million USD | 38.44% |
| 2008 Q1 | -33.44 Million USD | 0.0% |
| 2008 FY | -61.46 Million USD | -977.37% |
| 2008 Q3 | -9.02 Million USD | -65.13% |
| 2008 Q2 | -5.46 Million USD | 83.66% |
| 2008 Q4 | -13.52 Million USD | -49.89% |
| 2007 FY | -5.7 Million USD | 56.02% |
| 2007 Q1 | -2.94 Million USD | 0.0% |
| 2007 Q2 | -2.88 Million USD | 1.94% |
| 2006 FY | -12.97 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 141.807% |
| Embecta Corp. | 70.4 Million USD | 128.597% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 207.205% |
| Dynavax Technologies Corporation | -6.38 Million USD | -215.104% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 90.379% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 147.985% |
| PainReform Ltd. | -9.34 Million USD | -115.454% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -155.807% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -346.778% |
| SCYNEXIS, Inc. | 67.04 Million USD | 130.029% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -549.727% |
| Cosmos Health Inc. | -18.54 Million USD | -8.571% |
| Journey Medical Corporation | -3.85 Million USD | -422.502% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -346.778% |
| Safety Shot Inc | -15.08 Million USD | -33.474% |
| Alpha Teknova, Inc. | -36.78 Million USD | 45.264% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 85.586% |
| Bright Green Corporation | -13.12 Million USD | -53.356% |
| Procaps Group, S.A. | 42.54 Million USD | 147.325% |
| Theratechnologies Inc. | -23.95 Million USD | 15.966% |
| Harrow Health, Inc. | -24.41 Million USD | 17.529% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -316.381% |
| Biofrontera Inc. | -20.13 Million USD | -0.005% |
| DURECT Corporation | -27.62 Million USD | 27.121% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 1629.787% |
| Cronos Group Inc. | -73.96 Million USD | 72.781% |
| OptiNose, Inc. | -35.48 Million USD | 43.263% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 97.991% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 52.293% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 184.178% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 507.118% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | 12839.111% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -220.608% |
| Radius Health, Inc. | -25.79 Million USD | 21.942% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -226.656% |
| ProPhase Labs, Inc. | -16.78 Million USD | -19.962% |
| Phibro Animal Health Corporation | 2.41 Million USD | 933.278% |
| Procaps Group S.A. | 42.54 Million USD | 147.325% |
| Alvotech | -551.73 Million USD | 96.351% |
| TherapeuticsMD, Inc. | -10.27 Million USD | -95.875% |
| Viatris Inc. | 54.7 Million USD | 136.804% |
| Rockwell Medical, Inc. | -8.43 Million USD | -138.559% |
| Aytu BioPharma, Inc. | -15.84 Million USD | -27.064% |
| SIGA Technologies, Inc. | 68.06 Million USD | 129.576% |
| Tilray Brands, Inc. | -244.98 Million USD | 91.782% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 267.585% |
| Shineco, Inc. | -22.44 Million USD | 10.321% |
| PetIQ, Inc. | 2.13 Million USD | 1044.721% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -367.986% |
| Incannex Healthcare Limited | -18.45 Million USD | -9.063% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 108.062% |
| Silver Spike Investment Corp. | 7.34 Million USD | 374.274% |
| Assertio Holdings, Inc. | -331.94 Million USD | 93.935% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -205.367% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -146.619% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | -12.476% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -0.372% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 87.439% |
| Hempacco Co., Inc. | -13.12 Million USD | -53.374% |
| Talphera, Inc. | -18.39 Million USD | -9.431% |
| Alvotech | -551.73 Million USD | 96.351% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 156.484% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 106.163% |
| Currenc Group, Inc. | -15.3 Million USD | -31.525% |
| Kamada Ltd. | 8.28 Million USD | 343.023% |
| Indivior PLC | 2 Million USD | 1106.6% |
| Evoke Pharma, Inc. | -7.79 Million USD | -158.358% |
| Flora Growth Corp. | -57.03 Million USD | 64.703% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -0.372% |
| Evolus, Inc. | -61.68 Million USD | 67.363% |
| HUTCHMED (China) Limited | 100.78 Million USD | 119.976% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 114.637% |
| Akanda Corp. | -32.27 Million USD | 37.624% |